Severe Acute Respiratory Syndrome (SARS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Severe Acute Respiratory Syndrome (SARS) Market Outlook

Thelansis’s “Severe Acute Respiratory Syndrome (SARS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Severe Acute Respiratory Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Severe Acute Respiratory Syndrome Overview

Severe acute respiratory syndrome (SARS) is a human viral respiratory disease caused by the SARS coronavirus (SARS-CoV). The virus is a member of the coronavirus family, characterized by its crown-like glycoprotein spikes and large single-stranded RNA structure. SARS-CoV is thought to have originated from an animal reservoir in the horseshoe bat and transmitted to humans through an intermediate host in the palm civet. SARS presents a severe form of pneumonia and typically begins with flu-like symptoms, including fever, fatigue, headache, chills, muscle pain, loss of appetite, and diarrhea after an incubation period of 2-10 days. SARS-CoV uses the angiotensin-converting enzyme 2 (ACE2) receptor to enter the host and concentrate in the lungs and small intestine, areas with high receptor density. The infection leads to lung injury and serous pleural effusions and may result in secondary bacterial, viral, or fungal infections. Other causes of community-acquired pneumonia and ARDS must be considered as differentials. SARS may result in several pulmonary and extrapulmonary complications, including spontaneous pneumomediastinum, renal and hepatic impairment, leukopenia, thrombocytopenia, diastolic cardiac dysfunction, pulmonary hypertension, neurologic disorders, rhabdomyolysis. Risk factors for poor outcomes in SARS patients include diabetes, chronic hepatitis B, older age, non-typical presentation, and elevated serum lactate dehydrogenase (LDH). A high viral load at presentation has also been associated with a worse prognosis.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: